$PULM
Pulmatrix Inc Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011630 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$5.885M	$2.202M	$7.298M
YoY Change	292.6%	28.92%	20.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.626M	$911.0K	$6.520M
YoY Change	-26.43%	-41.83%	-3.81%
% of Gross Profit
Research & Development	$3.512M	$3.516M	$15.52M
YoY Change	-9.34%	-21.29%	-14.92%
% of Gross Profit
Depreciation & Amortization	$59.00K	$34.00K	$134.0K
YoY Change	84.38%	-12.82%	-17.28%
% of Gross Profit
Operating Expenses	$5.138M	$4.427M	$22.04M
YoY Change	-15.55%	-26.62%	-11.91%
Operating Profit	$747.0K		-$14.74M
YoY Change	-116.29%		-22.2%
Interest Expense	$160.0K	$192.0K	$867.0K
YoY Change	-27.93%	0.52%	180.58%
% of Operating Profit	21.42%
Other Income/Expense, Net	$78.00K	-$50.00K	$619.0K
YoY Change	-43.07%	-39.02%	457.66%
Pretax Income	$825.0K	-$2.083M	-$14.12M
YoY Change	-118.55%	-50.59%	-25.03%
Income Tax	$0.00
% Of Pretax Income	0.0%
Net Earnings	$825.0K	-$2.083M	-$14.12M
YoY Change	-118.55%	-50.59%	-25.03%
Net Earnings / Revenue	14.02%	-94.6%	-193.49%
Basic Earnings Per Share	$0.23		-$3.87
Diluted Earnings Per Share	$0.23	-$0.57	-$3.87
COMMON SHARES
Basic Shares Outstanding	3.652M shares	3.652M shares	3.652B shares
Diluted Shares Outstanding	3.652M shares		3.652B shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.30M	$19.17M	$19.17M
YoY Change	-47.0%	-46.19%	-46.19%
Cash & Equivalents	$16.30M	$19.17M	$19.17M
Short-Term Investments
Other Short-Term Assets	$712.0K	$742.0K	$742.0K
YoY Change	-45.52%	-39.23%	-39.23%
Inventory
Prepaid Expenses
Receivables	$570.0K	$928.0K	$928.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.58M	$20.84M	$20.84M
YoY Change	-46.4%	-45.36%	-45.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.108M	$1.158M	$11.47M
YoY Change	445.81%	392.77%	1113.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$135.0K	$176.0K	$1.648M
YoY Change	-84.98%	-54.76%	-11.45%
Total Long-Term Assets	$12.81M	$13.12M	$13.12M
YoY Change	293.03%	367.39%	367.39%
TOTAL ASSETS
Total Short-Term Assets	$17.58M	$20.84M	$20.84M
Total Long-Term Assets	$12.81M	$13.12M	$13.12M
Total Assets	$30.39M	$33.96M	$33.96M
YoY Change	-15.72%	-17.08%	-17.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$721.0K	$1.915M	$1.915M
YoY Change	24.74%	61.2%	61.2%
Accrued Expenses	$1.907M	$1.277M	$1.277M
YoY Change	-21.88%	-48.82%	-48.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.144M	$3.909M	$3.909M
YoY Change	-33.56%	-22.16%	-22.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$8.229M	$12.05M	$12.05M
YoY Change	90.62%	149.98%	149.98%
Total Long-Term Liabilities	$8.229M	$12.05M	$12.05M
YoY Change	90.62%	149.98%	149.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.144M	$3.909M	$3.909M
Total Long-Term Liabilities	$8.229M	$12.05M	$12.05M
Total Liabilities	$11.37M	$15.96M	$15.96M
YoY Change	25.68%	62.16%	62.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$286.8M	-$287.6M
YoY Change	3.18%	5.16%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.02M	$18.00M	$18.00M
YoY Change
Total Liabilities & Shareholders Equity	$30.39M	$33.96M	$33.96M
YoY Change	-15.72%	-17.08%	-17.08%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$825.0K	-$2.083M	-$14.12M
YoY Change	-118.55%	-50.59%	-25.03%
Depreciation, Depletion And Amortization	$59.00K	$34.00K	$134.0K
YoY Change	84.38%	-12.82%	-17.28%
Cash From Operating Activities	-$2.719M	-$2.015M	-$15.99M
YoY Change	-44.83%	-60.07%	-17.42%
INVESTING ACTIVITIES
Capital Expenditures	$154.0K	$306.0K	$676.0K
YoY Change		3300.0%	686.05%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$154.0K	-$306.0K	-$676.0K
YoY Change		3300.0%	686.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$53.00K
YoY Change			-96.16%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.000K	$53.00K
YoY Change			-95.69%
NET CHANGE
Cash From Operating Activities	-$2.719M	-2.015M	-$15.99M
Cash From Investing Activities	-$154.0K	-306.0K	-$676.0K
Cash From Financing Activities		3.000K	$53.00K
Net Change In Cash	-$2.873M	-2.318M	-$16.61M
YoY Change	-41.07%	-54.14%	-8.81%
FREE CASH FLOW
Cash From Operating Activities	-$2.719M	-$2.015M	-$15.99M
Capital Expenditures	$154.0K	$306.0K	$676.0K
Free Cash Flow	-$2.873M	-$2.321M	-$16.66M
YoY Change	-41.7%	-54.09%	-14.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	PULM	Stock Issued During Period Value Adjustment Due To Reverse Stock Split StockIssuedDuringPeriodValueAdjustmentDueToReverseStockSplit		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	PULM	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts		usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2023	PULM	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2022Q4	PULM	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment		usd
CY2022Q4	PULM	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36199
CY2023	dei	Entity Registrant Name EntityRegistrantName	PULMATRIX, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1821392
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	36 Crosby Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bedford
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01730
CY2023	dei	City Area Code CityAreaCode	(781)
CY2023	dei	Local Phone Number LocalPhoneNumber	357-2333
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	PULM
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	9787896	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3652285	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19173000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35628000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	153000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	928000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1298000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	742000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1068000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	20843000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	38147000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1158000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10309000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	710000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	176000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	389000	usd
CY2023Q4	us-gaap	Assets Assets	33958000	usd
CY2022Q4	us-gaap	Assets Assets	40953000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1915000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1188000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	947000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1638000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	429000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	857000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	618000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1339000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3909000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5022000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3727000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4822000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8327000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	15963000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9844000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3639185	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3639185	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305592000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	304585000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-287597000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273476000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	17995000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31109000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33958000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40953000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7298000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6071000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6520000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6778000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	22038000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	25018000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14740000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18947000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	867000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	309000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-248000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-198000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	619000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	111000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14121000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18836000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.87
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.87
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.46
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.46
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3651911000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3651911000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3447701000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3447701000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47449000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1382000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1114000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18836000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31109000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31109000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	954000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14121000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	17995000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	17995000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14121000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18836000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	134000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	162000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1341000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1383000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	954000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1114000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-370000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1231000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-326000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	197000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-213000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	389000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	727000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	511000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1080000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	405000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3041000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1431000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1816000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-847000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15985000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19356000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	676000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-676000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1382000	usd
CY2022	PULM	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts	-152000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1230000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16608000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18212000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37253000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	55465000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20645000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37253000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19173000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35628000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	153000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20645000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37253000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9116000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	389000	usd
CY2022	PULM	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	1081000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_807_eus-gaap--NatureOfOperations_zjuqoAZ6cftl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_823_zuGIT4MZOHa8">Nature of the Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pulmatrix, Inc. (the “Company”) was incorporated in 2013 as a Delaware corporation. The Company is a clinical-stage biopharmaceutical company focused on the development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE<i><sup>™</sup></i>, is engineered to deliver small, dense particles with highly efficient dispersibility and delivery to the airways, which can be used with an array of dry powder inhaler technologies and can be formulated with a variety of drug substances. The Company is developing a pipeline of iSPERSE<i><sup>™</sup></i>-based therapeutic candidates targeted at prevention and treatment of a range of respiratory and other diseases with important unmet medical needs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_z10UJsyz3QEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zNQbvDcrado2">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue and estimates related to clinical trial accruals and upfront deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zUlZh83bZa46" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zBKqYHt11p5h">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, revenue from one customer accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zPbSGs53xHy5" title="Concentration risk percentage">100</span>% of revenue recognized in the accompanying consolidated financial statements. For the year ended December 31, 2022, revenue from one customer accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zg74dHxxmlQ5" title="Concentration risk percentage">99</span>% of revenue recognized in the accompanying consolidated financial statements. As of both December 31, 2023 and 2022, one customer accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z62b0iagjAwa" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zNaBPmZPlAIf" title="Concentration risk percentage">100</span></span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Deposits Money Market Deposits DepositsMoneyMarketDeposits	51000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	232000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	286000	usd
CY2023Q4	PULM	Prepaid Software And Hosting Costs PrepaidSoftwareAndHostingCosts	108000	usd
CY2022Q4	PULM	Prepaid Software And Hosting Costs PrepaidSoftwareAndHostingCosts	99000	usd
CY2023Q4	PULM	Prepaid Clinical And Consulting PrepaidClinicalAndConsulting	30000	usd
CY2022Q4	PULM	Prepaid Clinical And Consulting PrepaidClinicalAndConsulting	517000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	372000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	166000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	742000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1068000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2894000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2983000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1736000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2748000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1158000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	134000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	162000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	usd
CY2023Q4	PULM	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	389000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	347000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	475000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1130000	usd
CY2023Q4	PULM	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	42000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	99000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	947000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1638000	usd
CY2023	PULM	Agreement Description AgreementDescription	Pursuant to the Second Amendment, the Company and Cipla were each responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis.
CY2023Q4	PULM	Transaction Costs TransactionCosts	22000000.0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	954000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1114000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1753000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1430000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	593000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	695000	usd
CY2023	us-gaap	Lease Cost LeaseCost	2346000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2125000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3454000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1478000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1100	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0297	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1357000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1326000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1364000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1402000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1442000	usd
CY2023Q4	PULM	Lessee Operating Lease Liability Payments Due Year Six And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter	7711000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14602000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5846000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8756000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	429000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8327000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8756000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.059	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.060	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.079	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.049	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.031	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.025	pure
CY2023	PULM	Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences	-0.014	pure
CY2022	PULM	Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences	-0.009	pure
CY2023	PULM	Effective Income Tax Reconciliation Limitations On Credit And Net Operating Losses EffectiveIncomeTaxReconciliationLimitationsOnCreditAndNetOperatingLosses	0.017	pure
CY2022	PULM	Effective Income Tax Reconciliation Limitations On Credit And Net Operating Losses EffectiveIncomeTaxReconciliationLimitationsOnCreditAndNetOperatingLosses	0.008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.314	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.295	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	12866000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	11557000	usd
CY2023Q4	PULM	Deferred Tax Assets Deferred Expense Capitalized Research And Development DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopment	7642000	usd
CY2022Q4	PULM	Deferred Tax Assets Deferred Expense Capitalized Research And Development DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopment	4460000	usd
CY2023Q4	PULM	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2977000	usd
CY2022Q4	PULM	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	234000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1528000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	698000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	873000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	860000	usd
CY2023Q4	PULM	Deferred Tax Assets Deferred Expense Capitalized Startup DeferredTaxAssetsDeferredExpenseCapitalizedStartup	153000	usd
CY2022Q4	PULM	Deferred Tax Assets Deferred Expense Capitalized Startup DeferredTaxAssetsDeferredExpenseCapitalizedStartup	293000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1303000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2206000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27342000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20308000	usd
CY2023Q4	PULM	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	2816000	usd
CY2022Q4	PULM	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	194000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2816000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	194000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24526000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20114000	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	federal net operating loss carryforwards of approximately $58.1 million available to reduce future taxable income, of which $3.8 million is subject to expiration between 2026 and 2037 and $54.3 million may be carried forward indefinitely.
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	58100000	usd
CY2023	PULM	Operating Loss Carryforwards Expiration Date Description OperatingLossCarryforwardsExpirationDateDescription	expiration between 2030 and 2043.
CY2023	PULM	Deferred Tax Assets Tax Credit Carryforwards Expiration Date Description DeferredTaxAssetsTaxCreditCarryforwardsExpirationDateDescription	expiration at various times through 2043
CY2023Q4	PULM	Percentage Of Net Operating Losses Utilization PercentageOfNetOperatingLossesUtilization	0.50	pure
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4400000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	229000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	229000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	276000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	505000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1505799000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1589626000	shares

Files In Submission

Name	View Source	Status
0001493152-24-011630-index-headers.html	Edgar Link	pending
0001493152-24-011630-index.html	Edgar Link	pending
0001493152-24-011630.txt	Edgar Link	pending
0001493152-24-011630-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97-01.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pulm-20231231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pulm-20231231_cal.xml	Edgar Link	unprocessable
pulm-20231231_def.xml	Edgar Link	unprocessable
pulm-20231231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pulm-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix Inc Stock $pulm

2024 Q1 Form 10-K Financial Statement

#000149315224011630 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix Inc Stock $pulm

2024 Q1 Form 10-K Financial Statement

#000149315224011630 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix Inc Stock $pulm